CAR-T cell therapy has emerged as a transformative approach in treating B cell malignancies and multiple myeloma. However, this approach is in desperate need of refinement. While attacking tumor cells ...

The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made ...

Investor reaction to the deal was muted, with BMO Capital Markets analysts saying they "continue to look for more" from ...